US Biosimilars ‘Bumpy’ For Teva As It Prepares For Alvotech Inspection
CEO Hints At More Deals On The Horizon Despite A Degree Of Market Uncertainty
Offering the latest details on Teva’s biosimilars strategy, CEO Richard Francis spoke about how the firm is looking to bring Alvotech’s FDA filings to the finish line as well as hinting at future biosimilars partnership deals. At the same time, he acknowledged a “bumpy” US market with a degree of uncertainty that has led the firm to allocate capital accordingly.
